Dermatomycosis
disease diseaseOn this page
Summary
Dermatomycosis (MONDO:0002040) is a disease with 22 GWAS associations across 11 studies. A subtype of cutaneous mycosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- GWAS associations: 22
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | dermatomycosis |
| Mondo ID | MONDO:0002040 |
| MeSH | D003881 |
| DOID | DOID:1563 |
| UMLS | C0011630 |
| MedGen | 8330 |
| Is cancer (heuristic) | no |
Data availability: 22 GWAS associations (11 studies).
Disease family
This is a subtype of cutaneous mycosis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › fungal infectious disease › cutaneous mycosis › dermatomycosis
Related subtypes (4): subcutaneous mycosis, tinea infection, superficial mycosis, cutaneous basidiobolomycosis
Subtypes (3): lobomycosis, eumycotic mycetoma, chromomycosis
Genetics & variants
GWAS landscape
22 GWAS associations across 11 studies. Top hits map to 9 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| chr16:31083324 | 3e-39 | G | 0.07 | |
| rs11864806 | 1e-36 | ZNF646, PRSS53 | G | 0.06 |
| rs1421085 | 3e-35 | FTO | T | 0.06 |
| rs1794269 | 2e-21 | HLA-DQB1 - MTCO3P1 | C | 0.05 |
| rs9270430 | 3e-20 | HLA-DRB1 - HLA-DQA1 | C | 0.34 |
| chr6:32626377 | 6e-17 | G | 0.39 | |
| rs12123821 | 8e-17 | CCDST | C | 0.11 |
| rs61816761 | 9e-16 | FLG, CCDST | G | 0.17 |
| chr17:44096553 | 2e-15 | G | 0.05 | |
| rs1056441 | 2e-13 | LIME1 | T | 0.19 |
| rs62106252 | 5e-12 | LINC01865 | G | 0.09 |
| rs4689388 | 6e-12 | JAKMIP1-DT - WFS1 | G | 0.03 |
| rs73984689 | 8e-12 | KANSL1 | G | 0.04 |
| chr20:62352637 | 1e-11 | G | 0.2 | |
| rs146016115 | 1e-11 | RNU6-943P - OR10A6 | A | 0.47 |
| rs6425145 | 1e-11 | SLC25A38P1 - AIMP1P2 | T | 0.04 |
| chr1:8498680 | 2e-11 | A | 0.04 | |
| rs141992399 | 2e-11 | CARD9 | C | 0.85 |
| rs55818528 | 4e-11 | LYNX1-SLURP2 - LY6D | T | 0.03 |
| rs10772985 | 3e-07 | EEF1A1P16 - RNU6-837P | ? |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST90475560 | Verma A | 2024 | 97,617 | 302,401 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90477141 | Verma A | 2024 | 38,505 | 67,722 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90479769 | Verma A | 2024 | 38,505 | 67,722 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90477139 | Verma A | 2024 | 14,214 | 38,346 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90652080 | Liu TY | 2025 | 4,434 | 223,436 | Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population. |
| GCST90475565 | Verma A | 2024 | 2,597 | 442,435 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90475564 | Verma A | 2024 | 2,110 | 116,542 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90479768 | Verma A | 2024 | 2,110 | 116,542 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90477140 | Verma A | 2024 | 828 | 5,349 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90477152 | Verma A | 2024 | 609 | 58,181 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 1 |
| Tier 2: splice/UTR | 3 |
| Tier 3: regulatory | 0 |
| Tier 4: intronic/intergenic | 16 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 15 |
| low_freq (0.01-0.05) | 3 |
| rare (<0.01) | 2 |
| unknown | 0 |
Functional consequences
| Consequence | Count |
|---|---|
| intron_variant | 6 |
| unknown | 5 |
| intergenic_variant | 5 |
| 3_prime_UTR_variant | 2 |
| stop_gained | 1 |
| splice_donor_variant | 1 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| chr16:31083324 | 0.385 | 3e-39 | Tier 4: intronic/intergenic | |||||
| rs11864806 | 16 | 31083883 | G>A,C,T | 0.429 | 3_prime_UTR_variant | ZNF646, PRSS53 | 1e-36 | Tier 2: splice/UTR |
| rs1421085 | 16 | 53767042 | T>C | 0.407 | intron_variant | FTO | 3e-35 | Tier 4: intronic/intergenic |
| rs1794269 | 6 | 32706117 | C>G,T | 0.371 | intergenic_variant | HLA-DQB1 - MTCO3P1 | 2e-21 | Tier 4: intronic/intergenic |
| rs9270430 | 6 | 32590884 | C>G,T | 0.1 | intergenic_variant | HLA-DRB1 - HLA-DQA1 | 3e-20 | Tier 4: intronic/intergenic |
| chr6:32626377 | 0.095 | 6e-17 | Tier 4: intronic/intergenic | |||||
| rs12123821 | 1 | 152206676 | C>T | 0.047 | intron_variant | CCDST | 8e-17 | Tier 4: intronic/intergenic |
| rs61816761 | 1 | 152313385 | G>A,C,T | 0.016 | stop_gained | FLG, CCDST | 9e-16 | Tier 1: coding |
| chr17:44096553 | 0.217 | 2e-15 | Tier 4: intronic/intergenic | |||||
| rs1056441 | 20 | 63738996 | T>C,G | 0.266 | 3_prime_UTR_variant | LIME1 | 2e-13 | Tier 2: splice/UTR |
| rs62106252 | 2 | 408713 | G>A | 0.044 | intron_variant | LINC01865 | 5e-12 | Tier 4: intronic/intergenic |
| rs4689388 | 4 | 6268329 | G>A | 0.414 | intergenic_variant | JAKMIP1-DT - WFS1 | 6e-12 | Tier 4: intronic/intergenic |
| rs73984689 | 17 | 46107038 | G>A | 0.185 | intron_variant | KANSL1 | 8e-12 | Tier 4: intronic/intergenic |
| chr20:62352637 | 0.314 | 1e-11 | Tier 4: intronic/intergenic | |||||
| rs146016115 | 11 | 7914551 | A>T | 0.008 | intron_variant | RNU6-943P - OR10A6 | 1e-11 | Tier 4: intronic/intergenic |
| rs6425145 | 1 | 172875269 | T>A,C,G | 0.31 | intron_variant | SLC25A38P1 - AIMP1P2 | 1e-11 | Tier 4: intronic/intergenic |
| chr1:8498680 | 0.321 | 2e-11 | Tier 4: intronic/intergenic | |||||
| rs141992399 | 9 | 136365140 | C>G,T | 0.004 | splice_donor_variant | CARD9 | 2e-11 | Tier 2: splice/UTR |
| rs55818528 | 8 | 142780034 | T>C,G | 0.395 | intergenic_variant | LYNX1-SLURP2 - LY6D | 4e-11 | Tier 4: intronic/intergenic |
| rs10772985 | 12 | 17017066 | G>A,C | 0.05 | intergenic_variant | EEF1A1P16 - RNU6-837P | 3e-07 | Tier 4: intronic/intergenic |
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 0.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.